IP Library Granted Patent US 10,865,409
Granted Patent B2
US 10,865,409 · App. 14/343,306 · Granted Dec 15, 2020

Methods for tagging DNA-encoded libraries

Inventors: Anthony D. Keefe (Cambridge, MA); Richard W. Wagner (Cambridge, MA); Alexander Litovchick (Sudbury, MA); Matthew Clark (Lexington, MA); John W. Cuozzo (Natick, MA); Ying Zhang (Lexington, MA); Paolo A. Centrella (Acton, MA); Christopher D. Hupp (Shrewsbury, MA)
Assignee: X-Chem, Inc.
C12N15/1065C12N15/10C12N15/1068C12N15/1093C40B50/16C07B2200/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,865,409
App. No.
14/343,306
Granted
Dec 15, 2020
Kind
B2
Abstract

The present invention relates to oligonucleotide-encoded libraries and methods of tagging such libraries. In particular, the methods and oligonucleotides can include one or more 2′-substituted nucleotides, such as 2′-O-methyl or 2′-fluoro nucleotides, and other conditions or reagents to enhance enzyme ligation or one or more chemical functionalities to support chemical ligation.

Claims (25)

1. A method of tagging a first library comprising an oligonucleotide-encoded chemical entity, said method comprising:

(i) providing a single-stranded oligonucleotide headpiece having a first functional group and a second functional group, wherein said headpiece comprises at least one terminal 2′-substituted nucleotide comprising said second functional group, wherein said at least one terminal 2′-substituted nucleotide is at the 5′-terminus and/or the 3′-terminus of said headpiece;

(ii) binding said first functional group of said headpiece to a first component of said chemical entity, wherein said headpiece is directly connected to said first component or said headpiece is indirectly connected to said first component by a bifunctional linker; and

(iii) ligating said second functional group of said headpiece to a single-stranded oligonucleotide first building block tag to form a complex, wherein said first building block tag comprises at least one terminal 2′-substituted nucleotide at the 5′- and/or the 3′-terminus and said ligating forms a covalent bond between a 2′-substituted nucleotide on the headpiece and a 2′-substituted nucleotide on the first building block tag, and wherein the ligating is carried out using enzymatic ligation;

wherein said steps (ii) and (iii) can be performed in any order; and

wherein said first building block tag encodes for the binding reaction of said step (ii), thereby providing a tagged library.

2. The method of claim 1 , wherein said first building block tag further comprises at least one 2′-substituted nucleotide at an internal position.

3. The method of claim 1 or 2 , wherein each 2′-substituted nucleotide is, independently, 2′-O-methyl guanine, 2′-O-methyl uracil, 2′-O-methyl adenosine, 2′-O-methyl thymidine, 2′-O-methyl inosine, 2′-O-methyl cytidine, 2′-O-methyl diamino purine, 2′-fluoro guanine, 2′-fluoro uracil, 2′-fluoro adenosine, 2′-fluoro thymidine, 2′-fluoro inosine, 2′-fluoro cytidine, or 2′-fluoro diamino purine.

4. The method of claim 1 , wherein step (ii) comprises binding said headpiece directly to said first component.

5. The method of claim 1 , wherein step (ii) comprises binding said headpiece indirectly to said first component via a bifunctional linker.

6. The method of claim 1 , further comprising

(iv) binding a single-stranded oligonucleotide second building block tag to the 5′-terminus or 3′-terminus of said complex; and

(v) binding a second component of said chemical library to said first component, wherein said steps (iv) and (v) can be performed in any order.

7. The method of claim 6 , wherein said second building block tag comprises a 2′-substituted nucleotide at one or more of the 5′-terminus, the 3′-terminus, and/or the internal position of said second building block tag.

8. The method of claim 6 , wherein said step (iv) is carried out using enzymatic ligation.

9. The method of claim 1 or 6 , wherein said method further comprises separating said complex from any unreacted tag or unreacted headpiece before any one of binding steps (ii)-(v) and/or purifying said complex before any one of binding steps (ii)-(v).

10. The method of claim 1 , wherein said method further comprises binding one or more additional building block tags to said complex and binding one or more additional components to said complex.

11. The method of claim 1 , wherein said headpiece comprises a hairpin structure.

12. The method of claim 1 or 10 , wherein said headpiece, said first building block tag, said second building block tag, and/or said one or more additional building block tags, if present, further comprises a first library-identifying sequence, a use sequence, and/or an origin sequence.

13. The method of claim 1 , wherein said method further comprises binding a first library-identifying tag, a use sequence, an origin sequence, and/or a tailpiece to said complex.

14. The method of claim 1 , wherein said method comprises a plurality of headpieces.

15. The method of claim 1 or 8 , wherein said enzymatic ligation is carried out using RNA ligase.

16. The method of claim 15 , wherein said RNA ligase is T4 RNA ligase.

17. The method of claim 1 or 8 , wherein said enzymatic ligation is carried out using DNA ligase.

18. The method of claim 17 , wherein said DNA ligase is ssDNA ligase.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jan 15, 2021
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
To: JAGUAR HOLDING COMPANY I; JAGUAR HOLDING COMPANY II; PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
Reel/Frame 054931/0201 →
SECURITY INTEREST Recorded Dec 11, 2020
From: X-CHEM, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 054619/0407 →
RELEASE OF SECURITY INTEREST Recorded Jan 20, 2016
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
To: X-CHEM, INC.
Reel/Frame 037534/0983 →
SECURITY AGREEMENT Recorded Sep 2, 2015
From: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC; PPD DEVELOPMENT, L.P.; PHARMACO INVESTEMENTS, INC.; X-CHEM, INC.
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Reel/Frame 036528/0004 →
RELEASE OF SECURITY INTEREST Recorded Sep 2, 2015
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC; PPD DEVELOPMENT, L.P.; PHARMACO INVESTEMENTS, INC.; X-CHEM, INC.
Reel/Frame 036481/0051 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT Recorded Jun 12, 2015
From: X-CHEM, INC.
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 035900/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2014
From: KEEFE, ANTHONY D.; WAGNER, RICHARD W.; LITOVCHICK, ALEXANDER; CLARK, MATTHEW; CUOZZO, JOHN W.; ZHANG, YING; CENTRELLA, PAOLO A.; HUPP, CHRISTOPHER D.
To: X-CHEM, INC.
Reel/Frame 032852/0625 →
Continuity (3)
Provisional Application 61536929 · Sep 20, 2011
Provisional Application 61531820 · Sep 7, 2011
Related Publication 20140315762A1 · Oct 23, 2014